Cargando…

Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies

BACKGROUND: Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there app...

Descripción completa

Detalles Bibliográficos
Autores principales: Misra, Abhinav K., Wong, Nathan L., Healey, Terrance T., Lally, Edward V., Shea, Barry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591876/
https://www.ncbi.nlm.nih.gov/pubmed/34775966
http://dx.doi.org/10.1186/s12890-021-01737-7
_version_ 1784599346586583040
author Misra, Abhinav K.
Wong, Nathan L.
Healey, Terrance T.
Lally, Edward V.
Shea, Barry S.
author_facet Misra, Abhinav K.
Wong, Nathan L.
Healey, Terrance T.
Lally, Edward V.
Shea, Barry S.
author_sort Misra, Abhinav K.
collection PubMed
description BACKGROUND: Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there appear to be some patients with ILD and circulating MSAs who do not develop muscle or skin disease even after prolonged follow-up. We sought to determine whether ILD is equally or more common than myositis or dermatitis at the time of initial detection of MSAs. METHODS: We identified all patients found to have circulating MSAs at our institution over a 4-year period and assessed for the presence of lung, muscle, and skin disease at the time of initial detection of MSAs. Among those found to have ILD, we compared demographic and clinical features, chest CT scan findings, and outcomes between those with PM/DM-associated ILD and those with ILD but no muscle or skin disease. RESULTS: A total of 3078 patients were tested for MSAs, and of these 40 were positive. Nine different MSAs were detected, with anti-histidyl tRNA synthetase (anti-Jo-1) being the most common (35% of MSAs). Among patients with positive MSAs, 86% were found to have ILD, compared to 39% and 28% with muscle and skin involvement, respectively (p < 0.001). Fifty percent of all MSA-positive patients had isolated ILD, with no evidence of muscle or skin disease. Those with isolated ILD were more likely to be older and have fibrotic changes on chest CT, less likely to receive immunomodulatory therapy, and had worse overall survival. CONCLUSIONS: In this study we found that individuals with circulating MSAs were more likely to have ILD than classic muscle or skin manifestations of PM/DM at the time of initial detection of MSAs. Our findings suggest that the presence of ILD should be considered a disease-defining manifestation in the presence of MSAs and incorporated into classification criteria for PM/DM.
format Online
Article
Text
id pubmed-8591876
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85918762021-11-15 Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies Misra, Abhinav K. Wong, Nathan L. Healey, Terrance T. Lally, Edward V. Shea, Barry S. BMC Pulm Med Research Article BACKGROUND: Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there appear to be some patients with ILD and circulating MSAs who do not develop muscle or skin disease even after prolonged follow-up. We sought to determine whether ILD is equally or more common than myositis or dermatitis at the time of initial detection of MSAs. METHODS: We identified all patients found to have circulating MSAs at our institution over a 4-year period and assessed for the presence of lung, muscle, and skin disease at the time of initial detection of MSAs. Among those found to have ILD, we compared demographic and clinical features, chest CT scan findings, and outcomes between those with PM/DM-associated ILD and those with ILD but no muscle or skin disease. RESULTS: A total of 3078 patients were tested for MSAs, and of these 40 were positive. Nine different MSAs were detected, with anti-histidyl tRNA synthetase (anti-Jo-1) being the most common (35% of MSAs). Among patients with positive MSAs, 86% were found to have ILD, compared to 39% and 28% with muscle and skin involvement, respectively (p < 0.001). Fifty percent of all MSA-positive patients had isolated ILD, with no evidence of muscle or skin disease. Those with isolated ILD were more likely to be older and have fibrotic changes on chest CT, less likely to receive immunomodulatory therapy, and had worse overall survival. CONCLUSIONS: In this study we found that individuals with circulating MSAs were more likely to have ILD than classic muscle or skin manifestations of PM/DM at the time of initial detection of MSAs. Our findings suggest that the presence of ILD should be considered a disease-defining manifestation in the presence of MSAs and incorporated into classification criteria for PM/DM. BioMed Central 2021-11-14 /pmc/articles/PMC8591876/ /pubmed/34775966 http://dx.doi.org/10.1186/s12890-021-01737-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Misra, Abhinav K.
Wong, Nathan L.
Healey, Terrance T.
Lally, Edward V.
Shea, Barry S.
Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_full Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_fullStr Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_full_unstemmed Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_short Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_sort interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591876/
https://www.ncbi.nlm.nih.gov/pubmed/34775966
http://dx.doi.org/10.1186/s12890-021-01737-7
work_keys_str_mv AT misraabhinavk interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies
AT wongnathanl interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies
AT healeyterrancet interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies
AT lallyedwardv interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies
AT sheabarrys interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies